Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)

Stopped early · Phase 4

Conditions studied: Endocarditis

In brief

The purpose of this study is to determine the safety and compliance of initial intravenous (IV) antibiotics followed by oral antibiotic therapy following uncomplicated IVDA endocarditis. Endocarditis has a high rate of sickness and death, involves a long hospitalization and a long-term use of IV antibiotics necessitating six (6) weeks of in-patient hospital stay, and comes with a high cost.

Key facts

Study ID

NCT05156437

Run by

West Virginia University

People needed

5

Starts

2022-03-16

Expected to finish

2024-10-31

Last updated by the study team

2026-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The age of the patient is ≥ 18.
• The patient has undergone an urgent or emergent primary cardiac valvar operation as treatment for IVDA endocarditis, with blood cultures positive for Streptococcus, Enterococcus faecalis, Staphylococcus aureus, or coagulase-negative Staphylococci
• The patient has received 2 weeks of postoperative inpatient IV antibiotic therapy with negative blood cultures and no residual active infection by imaging (i.e. computerized axial tomography, echocardiography)
• The patient has the capacity to participate in a compliance tracking tool for medication administration (e.g. a centrally managed core site mobile Medisafe compliance https://www.medisafe.com/) as confirmed by both a physician and a care management team member

You may not qualify if…

• Inability to give informed consent
• Residual infection requiring IV antibiotic therapy
• Any persistent secondary noncardiac infection (e.g. infections of solid organs or joints)
• Known poor compliance or deemed incapable to comply with the compliance tracking tool
• Reduced absorption or inability to receive oral treatment due to a gastrointestinal disorder
• Any infection involving a more virulent organisms, such as fungal infections or infections with Serratia or HACEK infections (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella).
• Cancer not otherwise in remission or in need of current or future oncologic therapy
• Medically immunocompromised state
• Reoperative valvar operation for IVDA endocarditis
• History of habitual noncompliance
• Pregnancy
• Mental incapacity
• Unable to perform local or institutional medical and psychiatric follow up
• Unstable home environment
• Inadequate access to mobile cell service (geographic/rurality)

Where it is running

• WVU Heart and Vascular Institute — Morgantown, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.